Gyawali. MW. Gastroenterología, 4ed

140 Parte II Abordaje de enfermedades específicas

6. Malfertheiner P. The intriguing relationship of Helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer. Dig Dis . 2011;29:459–464. 7. Saenz JB, Mills JC. Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol . 2018;15:257–273. 8. Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroentero- logy . 2016;150:64–78. 9. Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carci- nogenesis. Cell Host Microbe . 2014;15:306–316. 10. Greenfield LK, Jones NL. Modulation of autophagy by Helicobacter pylori and its role in gastric carcinogenesis. Trends Microbiol . 2013;21:602–612. 11. Kuipers EJ. Review article: exploring the link between Helicobacter pylori and gastric cancer. Aliment Pharmacol Ther . 1999;13(Suppl 1):3–11. 12. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med . 1996;335:242–249. 13. Hu Q, Zhang Y, Zhang X, et al. Gastric mucosa-associated lymphoid tissue lymphoma and Heli- cobacter pylori infection: a review of current diagnosis and management. Biomark Res . 2016;4:15. 14. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev . 2008;88:1547–1565. 15. McColl KE. The elegance of the gastric mucosal barrier: designed by nature for nature. Gut . 2012;61:787–788. 16. Yandrapu H, Sarosiek J. Protective factors of the gastric and duodenal mucosa: an overview. Curr Gastroenterol Rep . 2015;17:24. 17. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti- inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet . 2002;359:14–22. 18. Komorowski RA, Caya JG. Hyperplastic gastropathy. Clinicopathologic correlation. Am J Surg Pathol . 1991;15:577–585. 19. Moayyedi P, Talley NJ, Fennerty MB, et al. Can the clinical history distinguish between organic and functional dyspepsia? JAMA . 2006;295:1566–1576. 20. Loy CT, Irwig LM, Katelaris PH, et al. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol . 1996;91:1138–1144. 21. Graham DY, Miftahussurur M. Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: a mini review. J Adv Res . 2018;13:51–57. 22. Hopper AN, Stephens MR, Lewis WG, et al. Relative value of repeat gastric ulcer surveillance gastroscopy in diagnosing gastric cancer. Gastric Cancer . 2006;9:217–222. 23. Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther . 2001;15:1949–1958. 24. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci . 2011;56:931–950. 25. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroentero- logy. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol . 2007;102:1808–1825. 26. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helico- bacter pylori infection in adults. Gastroenterology . 2016;151:51–69.e14. 27. Scarpignato C, Pelosini I. Prevention and treatment of non-steroidal anti-inflammatory drug- induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gas- troenterol Hepatol . 1999;31(Suppl 1):S63–S72. 28. Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology . 2018;154:500–514. 29. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol . 2006;101:701–710. 30. Barbateskovic M, Marker S, Granholm A, et al. Stress ulcer prophylaxis with proton pump inhi- bitors or histamin-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med . 2019;45:143–158. 31. Pilkington KB, Wagstaff MJ, Greenwood JE. Prevention of gastrointestinal bleeding due to stress ulceration: a review of current literature. Anaesth Intensive Care . 2012;40:253–259. 32. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high- risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med . 2014;174:1755– 1762. SAMPLE